Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAVO.L Regulatory News (AVO)

  • There is currently no data for AVO

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Appointment of Director

28 Jun 2012 07:00

RNS Number : 3062G
CareCapital Group plc
28 June 2012
 



28 June 2012

 

CARECAPITAL GROUP PLC

("CareCapital" or "the Company")

 

Appointment of Non-executive Director

 

CareCapital (AIM: CARE) is pleased to announce the appointment of Trevor Brown as a Non-executive Director with immediate effect.

 

Trevor Brown (66) has been a strategic investor in real estate and equities for more than 30 years. Mr Brown is a director of Free Association Books Limited in London.

 

He has a beneficial interest as at the date of this announcement in 15,334,001 ordinary shares of CareCapital, representing 9.38% of the Company's current issued share capital.

 

There is no further information required to be disclosed in relation to Rule 17 and Schedule 2 (g) of the AIM Rules for Companies.

 

Commenting on the appointment, Dr Mike Sinclair, CareCapital's CEO, said, "I am pleased that Trevor has agreed to join the Board as a Non-executive Director. He is, and has been, a supporter of our plans to refocus CareCapital on the provision of advanced cancer treatment services. His experience and track record will greatly benefit our Board, our management team and our shareholders. I welcome him to CareCapital."

 

For further information, please visit www.carecapital.co.uk or contact:

 

Michael Sinclair, CEO

 

Sandy Jamieson

Simon Hudson / Kelsey Traynor

CareCapital Group PlcLibertas Capital Corporate Finance Ltd

(NOMAD & Joint Broker)

Tavistock Communications

(Financial PR & IR)

 020 3617 8727

 

020 7569 9650

 

020 7920 3150

 

About CareCapital

CareCapital recently announced a restructuring to reflect its strategy to reposition the Company primarily as an investor in, and provider of, advanced cancer treatments. Current investments in medical centre development projects are to be transferred to the Company's wholly owned subsidiary - The Healthcare Property Company Limited - which will continue to progress existing schemes and expand through securing new medical centre projects in the UK. This company will also provide property related support services to the wider CareCapital group. The Company also announced that it will be seeking shareholder authority at the earliest opportunity to change its name to Advanced Oncotherapy plc.

 

CareCapital is building a portfolio of innovative cancer treatment services to capture opportunities in the cancer diagnosis and treatment market, building on its 28.75% stake in Advanced Proton Solutions (Holdings) Ltd and its newly launched Oncotherapy Resources business focused on early stage breast cancer treatment. Advanced Proton Solutions is pioneering the use of Proton Beam Therapy in the UK and which has secured planning approval for its first London based centre off Moorgate in the City of London, within easy access of a number of London's major hospitals.

 

CareCapital also specialises, as an innovative developer, in primary care real estate, particularly multi-occupancy premises that accommodate a variety of different, but often synergetic healthcare providers. This is particularly relevant at a time when the Government is intent on expanding primary care, bringing more services together under one roof and closer to patients in their own communities. Working in partnership with local authorities, projects can involve significant urban regeneration, with mixed-use and mixed-economy developments incorporating housing, healthcare, childcare, retail and other appropriate facilities for the community.

 

-ends-

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOABKODNABKDQAB
Date   Source Headline
27th Aug 20197:00 amRNSTotal Voting Rights and Directors' Shareholdings
8th Aug 201910:45 amEQSHardman & Co Research: Advanced Oncotherapy (AVO): Nearing the end-goal
7th Aug 20197:00 amRNSIssue of equity and new debt facility
6th Aug 201911:05 amRNSSecond Price Monitoring Extn
6th Aug 201911:00 amRNSPrice Monitoring Extension
25th Jul 20195:12 pmRNSResult of AGM
25th Jul 20197:00 amRNSAGM Statement & Technological update
22nd Jul 20197:00 amRNSHarley Street update
28th Jun 20197:00 amRNSFinal Results
3rd Jun 20197:00 amRNSTechnological update
31st May 20195:30 pmRNSTotal Voting Rights
17th May 20195:29 pmRNSHolding(s) in Company
16th May 20192:23 pmEQSAdvanced Oncotherapy (AVO-GB): Strong fundamentals underpin future growth
13th May 201912:20 pmEQSHardman & Co Research: Advanced Oncotherapy (AVO): Commercialising a breakthrough technology
10th May 20197:00 amRNSDebt facility secured
16th Apr 201910:26 amEQSHardman & Co Research: Advanced Oncotherapy (AVO): Preparing for commercialisation
16th Apr 20199:12 amEQSAdvanced Oncotherapy (AVO-GB): Key talent acquisition reaffirms the promise of LIGHT
16th Apr 20197:00 amRNSSenior Management Appointment
7th Mar 20199:00 amRNSPrice Monitoring Extension
22nd Feb 20197:00 amRNSGrant of options
1st Feb 20197:00 amRNSAppointment of Nominated Adviser and Joint Broker
30th Jan 201911:45 amRNSSchedule 2(g) Disclosure
29th Jan 20199:38 amRNSTotal Voting Rights and Significant Shareholdings
24th Jan 201912:14 pmRNSSchedule 2(g) Disclosure
22nd Jan 20193:29 pmRNSResult of General Meeting
21st Jan 201911:15 amEQSHardman & Co Research: Advanced Oncotherapy (AVO): Important regulatory milestone: ISO approval
21st Jan 20197:00 amRNSISO 13485:2016 certification for medical devices
21st Dec 201810:15 amRNSLaunch of 2018 SAYE Scheme
21st Dec 20187:00 amRNSProposed Direct Subscription to raise £10.0m
16th Oct 20184:31 pmEQSHardman & Co Research: Advanced Oncotherapy (AVO): Four components integrated
16th Oct 20183:58 pmEQSHardman & Co Research: Advanced Oncotherapy (AVO): Treatment planning system agreement
10th Oct 20187:30 amRNSGPSL Research - Flash Note on AVO
10th Oct 20187:00 amRNSTechnological update
4th Oct 201811:07 amRNSGPSL Research - Flash Note on AVO
28th Sep 20187:00 amRNSHalf-year Report
27th Sep 20187:00 amRNSTechnological update
10th Sep 201811:32 amRNSHolding(s) in Company
7th Sep 201811:52 amRNSHolding(s) in Company
3rd Sep 20185:15 pmEQSHardman & Co Research: Advanced Oncotherapy (AVO): Treatment planning system agreement
3rd Sep 201811:38 amRNSCompletion of the £6.41m Placing
29th Aug 20189:57 amEQSHardman & Co Research: Advanced Oncotherapy (AVO): Treatment planning system agreement
28th Aug 20187:00 amRNSDirector Declaration
9th Aug 20187:00 amRNSExercise of Warrants and Issue of Shares
2nd Aug 20187:00 amRNS£6.41m Placing
25th Jul 20183:34 pmRNSResult of AGM
4th Jul 20184:40 pmRNSSecond Price Monitoring Extn
4th Jul 20184:35 pmRNSPrice Monitoring Extension
4th Jul 201811:05 amRNSSecond Price Monitoring Extn
4th Jul 201811:00 amRNSPrice Monitoring Extension
4th Jul 20189:05 amRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.